News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

VIVUS, Inc. (VVUS) Doubles After Winning Panel Backing for First Weight-Loss Pill in 13 Years



2/23/2012 6:58:39 AM

Vivus Inc. more than doubled in early trading after the company's weight-loss pill Qnexa won the backing of a U.S. advisory panel, moving a step closer to gaining approval as the first new obesity drug in 13 years. Vivus gained $12.20 to $22.75 at 7:44 a.m. The shares of NeuroSearch A/S and Novo Nordisk A/S, Danish companies developing obesity treatments, also gained after advisers to the Food and Drug Administration voted 20-2 yesterday that Qnexa's benefits outweigh its risks. The FDA isn't required to follow the panel's recommendation.

Read at BusinessWeek
Read at Reuters
Read at Baltimore Sun
Read at CBS News
Read at SF Gate
Read at Los Angeles Times


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES